Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Volagidemab · AMG-477, REMD-477

Monoclonal antibody · Antagonist of glucagon receptor (GCGR) · developed by REMD Biotherapeutics

Phase 1/2 Most advanced trial
1 Registered trials

What is Volagidemab?

Volagidemab is a fully human IgG2 monoclonal antibody that binds and blocks the glucagon receptor. By inhibiting glucagon signaling, it decreases hepatic glycogenolysis and gluconeogenesis to lower blood glucose levels. It is studied in type 1 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMG-477, REMD-477
Drug type
Monoclonal antibody
Targets
glucagon receptor (GCGR)
Mechanism
Antagonist of glucagon receptor (GCGR)
Pathways
hepatic glycogenolysis, gluconeogenesis
Therapy area
Endocrine
Developer
REMD Biotherapeutics, Inc.
In trials of
LXRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
77JYS6UZ0M

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05696366 Phase 1/2 Type 1 Diabetes Active not recruiting LXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type 1 Diabetes

Other drugs acting on GCGR

Glucagon FDA approved XeriSol glucagon Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.